Biomarin Pharma

VIMIZIM

Manufacturer:

Biomarin Pharma

Vimizim HCPCS:

J1322

HCPCS Code Descriptor:

Injection, elosulfase alfa, 1 mg

Category:

J Code

Vimizim NDCs:

68135-0100-01

Primary Type:

Enzyme Replacement Therapy

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Vimizim CPT Codes:

Potential CPT administration codes for Vimizim can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Vimizim:

VIMIZIM is an Enzyme Replacement Therapy drug manufactured by Biomarin Pharma and administered via the Intravenous route of administration. The J Code: J1322 is aligned to the drug VIMIZIM.

ACCESS PRICING AND MORE BY REGISTERING

J1322 Added Date:

January 1, 2015

J1322 Effective Date:

January 1, 2015

J1322 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Vimizim billing and coding information.
Vimizim patient assistance information can be found through BioMarin RareConnections at the URL: https://www.biomarin-rareconnections.com/
VIMIZIM prescribing information can be found at the link below:
Our team has not yet identified a source of side effects information for VIMIZIM. Please check back in a few weeks.